H.R. 2884 117th Congress
Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act
- Commerce
- Sponsor: Rep. Johnson, Henry C. "Hank," Jr. [D-GA-4]
- Congress.gov ↗
Latest action, Sep 30, 2021: Ordered to be Reported in the Nature of a Substitute by Voice Vote.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
2 cosponsors
Sponsored by Rep. Johnson, Henry C. "Hank," Jr. [D-GA-4] (Democrat). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
1 D · 1 R
Referred to: House: Judiciary Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
7 reports
7 reports
7 reports
JOHNSON & JOHNSON SERVICES, INC.
BROWNSTEIN HYATT FARBER SCHRECK, LLP
7 reports
6 reports
6 reports
6 reports
ELI LILLY & COMPANY
WILLIAMS AND JENSEN, PLLC
6 reports
6 reports
6 reports
NOVO NORDISK INC.
WILLIAMS AND JENSEN, PLLC
6 reports
PFIZER
WILLIAMS AND JENSEN, PLLC
6 reports
All 25 of 26 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| ASTRAZENECA PHARMACEUTICALS LP | 7 | $8.2M | Q4 2021 | Q3 2022 | yes | |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 7 | $23.5M | Q4 2021 | Q3 2022 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 7 | $8.0M | Q4 2021 | Q3 2022 | yes | |
| JOHNSON & JOHNSON SERVICES INC | 7 | $11.4M | Q4 2021 | Q3 2022 | yes | |
| JOHNSON & JOHNSON SERVICES, INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 7 | $0 | Q4 2021 | Q3 2022 | yes |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 7 | $14.1M | Q4 2021 | Q3 2022 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 7 | $49.3M | Q4 2021 | Q3 2022 | yes | |
| ABBVIE INC. | 6 | $11.4M | Q4 2021 | Q3 2022 | yes | |
| AMGEN INC | 6 | $15.2M | Q4 2021 | Q3 2022 | yes | |
| CHAMBER OF COMMERCE OF THE U.S.A. | 6 | $115.3M | Q4 2021 | Q3 2022 | yes | |
| ELI LILLY & COMPANY | WILLIAMS AND JENSEN, PLLC | 6 | $0 | Q4 2021 | Q3 2022 | yes |
| NATIONAL MULTIPLE SCLEROSIS SOCIETY | 6 | $313K | Q4 2021 | Q3 2022 | yes | |
| NOVARTIS | 6 | $8.4M | Q4 2021 | Q3 2022 | yes | |
| NOVO NORDISK INC. | WILLIAMS AND JENSEN, PLLC | 6 | $0 | Q4 2021 | Q3 2022 | yes |
| PFIZER | WILLIAMS AND JENSEN, PLLC | 6 | $0 | Q4 2021 | Q3 2022 | yes |
| PHRMA | WILLIAMS AND JENSEN, PLLC | 6 | $300K | Q4 2021 | Q3 2022 | yes |
| REGENXBIO | 6 | $507K | Q4 2021 | Q3 2022 | yes | |
| TEVA PHARMACEUTICALS USA INC | 6 | $5.3M | Q4 2021 | Q3 2022 | yes | |
| CONSERVATIVES FOR PROPERTY RIGHTS | JAMES EDWARDS | 5 | $120K | Q4 2021 | Q3 2022 | yes |
| GENENTECH INC | 5 | $10.0M | Q4 2021 | Q3 2022 | yes | |
| ASSOCIATION FOR ACCESSIBLE MEDICINES | 4 | $2.8M | Q4 2021 | Q1 2022 | yes | |
| PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC | COVINGTON & BURLING LLP | 4 | $0 | Q4 2021 | Q2 2022 | yes |
| TRAVERE THERAPEUTICS | 4 | $810K | Q1 2022 | Q3 2022 | yes | |
| BIOGEN | 2 | $1.8M | Q2 2022 | Q3 2022 | yes | |
| PARTNERSHIP TO FIGHT CHRONIC DISEASE | JAMES P. KEESE | 2 | $38K | Q2 2021 | Q3 2021 | yes |